Immunogenicity assessment and de-immunization during the development of antibody therapeutics

Abstract

Immunogenicity (the development of anti-drug antibodies) is an important concern for both the safety and efficacy of engineered protein therapeutics. The accurate estimation of immunogenic potential and appropriate de-immunization are required in non-clinical development. This talk will present overview of clinical immunogenicity and impact, current situation of non-clinical assessments of immunogenicity, and examples of de-immunization of antibody therapeutics.